Cameron Santoro

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.

Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.

Dermatology providers reported strong impacts on the work and home life of patients with moderate to severe chronic hand eczema, a manifestation of atopic dermatitis.

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and barzolvolimab showing complete response in patients, particularly among those who are difficult to treat.

Raj Chovatiya, MD, PhD, MSCI, highlights the long-term effectiveness of lebrikizumab across diverse patients, including those with prior biologic use, positioning it as a potential first-line treatment for moderate to severe atopic dermatitis.

Patients with chronic spontaneous urticaria experienced a long delay in diagnosis, a substantial impact on their quality of life, and often received inadequate treatment, highlighting the need for better management and understanding of the condition.

Pediatric patients with prior SARS-CoV-2 infection had a higher risk of adverse postacute kidney outcomes, such as new-onset chronic kidney disease (CKD) and declining kidney function, if they had preexisting CKD or acute kidney injury.

With deadlines looming in 2026 and 2027 for compliance with the CMS Advancing Interoperability and Improving Prior Authorization Final Rule, a survey indicates a concerning lack of readiness among payers and providers to meet the new requirements for data sharing.

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

US migrant populations experience various dermatologic conditions linked to exposures before, during, and after migration, often exacerbated by barriers to accessing health care.

Research presented at the 2025 Academy of Managed Care Pharmacy annual meeting analyzed real-world treatment outcomes for dermatologic conditions, specifically highlighting the efficacy of ruxolitinib cream for atopic dermatitis and the potential for phototherapy to delay costly biologic initiation.

The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and favorable hematological safety profile of remibrutinib, were highlighted at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.

National Infertility Awareness Week highlights that infertility impacts both men and women, is more prevalent among Black and Hispanic/Latina women, is not caused by contraceptives, and becomes more challenging to address with time.

Accessing equitable health care is an ongoing struggle in the US for minority communities due to historical pretexts with new setbacks surfacing as recent administrative changes emerge, highlighting the urgent need for continued advocacy during National Minority Health Month.

Hispanic and Latino adults found that while preserving cultural identity may initially benefit health, socioeconomic factors like education level significantly impact diabetes and hypertension rates, highlighting the need for targeted health interventions across diverse subgroups.

Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.

Interval breast cancer rates have remained consistent over 30 years despite age-based screening, highlighting the need for risk-based screening strategies that account for factors like breast density, hormone replacement therapy, and family cancer history to improve early detection.

Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, advocates for increased funding and education to address hair loss disparities within the African diaspora, emphasizing the need for culturally sensitive treatment and research.

Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological diseases through teledermatology.

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, highlights the continued relevance of older, generic dermatologic therapies despite the availability of newer, targeted treatments.

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.

Experts discussed advancements in dermatology treatment while emphasizing the value of in-person collaboration and professional rejuvenation at the American Academy of Dermatology 2025 conference.

In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric alopecia areata and highlights the need for personalized treatment approaches based on Janus kinase inhibitor responses.

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic dermatitis, its potential to reduce the need for systemic therapies, and the significant role of the skin microbiome in disease management.

Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.

Steven Daniel Daveluy, MD, FAAD, advocates for dermatologists to adopt cultural humility, engage in continuous education, and navigate ethical considerations to provide equitable and supportive care to LGBTQ patients.

Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ruxolitinib for itch and inflammation, while also outlining a comprehensive approach to chronic pruritus management.